move filgotinib timelin posit us file updat new pt vs
invest summari reiter overweight rate increas
price target posit us file updat filgotinib could
move timelin least year increas dcf
announc today path forward file filgotinib us
year base case assum us launch sale
shift timelin potenti approv therefor estim
filgotinib could market year also note key
commerci posit given nc seek approv upadacitinib
may market shorten lead well-establish
player year new estim us sale
respect vs previous
speak manag believ compani remain
confid new timelin file us manta on-going
doesnt remain condit file compani includ
week data file avail sometim gilead expect
file gilead base case sg includ infrastructur spend
us would expect trend acceler rest
year chang estim hear manag say
compani one prioriti review voucher guess
use filgotinib model modest sale
think risk/benefit profil filgotinib remain attract
filgotinib gild import pipelin asset drive near-term revenu
estim ra filgotinib sale ex-u
expect compani sg increas faster sinc unsur us
filgotinib launch case gilead model guidanc also adjust eu launch
model sale eu file remain
view registr pathway clearer updat
shift timelin filgotinib increment help three-year top-and
bottom-lin growth profil still look compani add pipelin
revenu drive growth new top bottom line four-year cagr
vs previou remain earli mr day time
ceo curiou gilead strateg direct remain
posit share current level think base busi
mostli stabl expect new manag drive pipelin top-lin
revenu growth next month
disclosur section may found page
use probability-adjust dcf analysi valu gilead share assum discount rate
model revenu assum termin valu
risk overweight rate price target includ hiv gener competit risk
particularli gsk cover brand side slower less-success biktarvi
launch expect slow car-t sale current competit emerg next-gen
car-t failur cell therapi modal grow drive stabil growth long term
late-stag pipelin failur particularli nash franchis filgotinib trial
clinic regulatori commerci risk prevent franchis contribut
million except ep
hiv hbv
royalti contract revenu
product revenu
provis incom tax
net incom gilead non-
net incom non-control interest
net loss non-control interest
growth ep dilut
net incom
million except ep
non- reconcili
acquisit relat amort intang
acquisition-rel amort inventori mark-up
acquisit relat amort intang
non- incom expens
incom tax effect non-gaap adjust
tax non-gaaap adjust
cog total
 total
sg total
issuanc stock share buyback
chang work capit
present valu flow
npv
npv termin valu
tv
patient number
econom gilead unadjust sale
eu revenu glpg co-promo territori
total net sale gilead
econom gilead adjust sale
eu revenu glpg co-promo territori
total net sale gilead
impli penetr total treat ra patient
impli penetr total treat ra patient
gilead global biopharmaceut compani major base busi revenu base infecti diseas
pipelin evolv inflamm oncolog nash compani headquart foster citi california
